

What is Claimed is:

1. A veterinary formulation comprising a 13-monosaccharide 5-oxime avermectin at around 1% to 16% w/v, and praziquantel at around 0.5-10% w/v, in a veterinarily acceptable carrier, diluent or adjuvant.
2. The formulation according to claim 1 wherein the 13-monosaccharide 5-oxime avermectin is selamectin.
3. The formulation according to claim 1 wherein the praziquantel is present at around 6% w/v.
4. The formulation according to claim 1 which further comprises a di(C₂₋₄ glycol) mono(C₁₋₄ alkyl) ether and an optional skin-acceptable solvent.
5. The formulation according to claim 1 which is suitable for topical application or spot-on application.
6. The formulation according to claim 1 wherein the 13-monosaccharide 5-oxime avermectin is provided at around 6-12mg/kg (with respect to the host animal) and praziquantel is provided at up to 18mg/kg (with respect to the host animal).
7. The formulation according to claim 1 wherein the 13-monosaccharide 5-oxime avermectin is present at about 6% to about 12% w/v.
8. The formulation according to claim 1 wherein the praziquantel is present in the formulation at about 3% to about 9% w/v.
9. The formulation according to claim 1 wherein the praziquantel is present in the formulation at about 6% w/v.
10. The formulation according to claim 1 wherein a di(C₂₋₄ glycol) mono(C₁₋₄ alkyl) ether is present, said ether being diethylene glycol monomethyl ether (DEGMME) or dipropylene glycol monomethyl ether (DPGMME).

11. The formulation according to claim 1 wherein a skin-acceptable solvent is present, said solvent being ethanol or isopropanol.

12. The formulation according to claim 1 which consists of:

- (a) selamectin, at a level of 1% to 16% w/v;
 - (b) DEGMME or DPGMME at 1 to 16% w/v, and at a w/v or v/v ratio of active compound to DEGMME/DPGMME of about 1:1;
 - (c) praziquantel at 0.5 to 10% w/v;
 - (d) isopropanol to volume (100%);
- and, optionally (e) BHT (at less than 0.1% w/v).

13. A method of treatment and prophylaxis of parasitic infestation of flea, heartworm or tapeworm in a mammal which comprises administering to said mammal an amount of a 13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and an amount of praziquantel, each amount being effective to treat or provide prophylaxis to the mammal.

14. The method according to claim 13 wherein the 13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel are administered separately in different formulations.

15. The method according to claim 13 wherein the 13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel are administered in the same formulation.

16. The method according to claim 13 wherein the 13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel are administered via the same route.

17. The method according to claim 13 wherein the 13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel are administered via different routes.

18. The method according to claim 13 wherein the mammal is a companion animal, selected from the group consisting of a cat.

19. A kit useful in the treatment or prophylaxis of a parasitic infestation of flea, heartworm or tapeworm in a mammal, which comprises a 13-monosaccharide 5-oxime avermectin, selected from the group consisting of selamectin, and praziquantel and a pharmaceutical or veterinary carrier, and instructions for the treatment of a parasitic infestation of flea, heartworm or tapeworm in a mammal.